Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 79Other hematologic neoplasm 59Thoracic 30CNS 26Sarcoma 21Myeloid 12Genitourinary 9Classical hematology 8Plasma cell 6Endocrine 4Other solid neoplasm 3Gynecologic 3Dermatologic 3Breast 3Tumor-Agnostic 1NET 1Head & Neck 1

Conditions

Neoplasms, Unknown Primary 1

Interventions

Specimen Handling 19Biopsy 18Magnetic Resonance Spectroscopy 12Paclitaxel 9trastuzumab deruxtecan 4olaparib 4X-Rays 4Taxes 4nilotinib 3Radiotherapy 3Gemcitabine 3Cisplatin 3Carboplatin 3Bevacizumab 3trametinib 2talazoparib 2pembrolizumab 2omipalisib 2durvalumab 2copanlisib 2aldesleukin 2Vincristine 2Topotecan 2Phantoms, Imaging 2Leucovorin 2Immunoglobulin G 2Fluorouracil 2Doxorubicin 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Etoposide × Tumor-Agnostic × Clear all
NCT00003558 2013-08-07

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

National Cancer Institute (NCI)

Phase 3 Unknown
140 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡